

CHICAGO IL SITE LIST

NAME	ADDRESS	CITY	STATE	ZIP	PHONE	STUDY_ID	TITLE	DESCRIPTION
Uptown Research Institute, LLC	1021 W Lawrence Ave	Chicago	IL	60640	773-989-8313	031-201-00301	A Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months with aripiprazole tablet with sensor	To compare inpatient psychiatric hospitalization rates while subjects are on oral standard-of-care antipsychotic treatment and later switched to aripiprazole tablet with sensor. This trial will include male and female subjects who are 18 to 65 years old and diagnosed with schizophrenia. The trial will be conducted at 75 sites in the United States, with the a target of enrolling 320 subjects. Subject participation is approximately 8 months, including a 45-day screening period, a required 3 months (Months 1 to 3) of aripiprazole tablet with sensor treatment. This will be followed to either a change back to standard-of-care antipsychotic treatment or remain on aripiprazole tablet with sensor for an additional 3 months (Months 4-6). All subjects who complete or withdraw from the trial while on aripiprazole tablet with sensor will receive a telephone call for safety follow-up approximately 30 days after their last trial visit.
Alexian Brothers Center for Psychiatric Research	1786 Moon Lake Blvd 200	Hoffman Estates	IL	60169	847 882-4781	031-201-00301	A Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months with aripiprazole tablet with sensor	To compare inpatient psychiatric hospitalization rates while subjects are on oral standard-of-care antipsychotic treatment and later switched to aripiprazole tablet with sensor. This trial will include male and female subjects who are 18 to 65 years old and diagnosed with schizophrenia. The trial will be conducted at 75 sites in the United States, with the a target of enrolling 320 subjects. Subject participation is approximately 8 months, including a 45-day screening period, a required 3 months (Months 1 to 3) of aripiprazole tablet with sensor treatment. This will be followed to either a change back to standard-of-care antipsychotic treatment or remain on aripiprazole tablet with sensor for an additional 3 months (Months 4-6). All subjects who complete or withdraw from the trial while on aripiprazole tablet with sensor will receive a telephone call for safety follow-up approximately 30 days after their last trial visit.
Rush University Medical Center	1645 West Jackson Blvd Suite 603	Chicago	IL	60612	312-563-3352	331-10-234	Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents with Schizophrenia	To determine the safety & efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
Rush University Medical Center	1645 West Jackson Blvd Suite 603	Chicago	IL	60612	312-563-3352	331-10-236	Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia	To further characterize the long-term safety and tolerability of brexpiprazole in adolescents with schizophrenia
Chicago Research Center	3401 N Central Ave	Chicago	IL	60634-4426	773-282-9845	331-201-00079	A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults with Major Depressive Disorder	Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term outcomes remains challenging. This study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open label antidepressant therapy.
Pillar Clinical Research	6865 N. Lincoln Avenue	Lincolnwood	IL	60712	224-534-7332 ext.546	331-201-00079	A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults with Major Depressive Disorder	Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term outcomes remains challenging. This study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open label antidepressant therapy.
Pillar Clinical Research	6865 N. Lincoln Avenue	Lincolnwood	IL	60712	PTSDStudies.com	331-201-00072	Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder	This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of fixed-dose brexpiprazole + sertraline combination treatment in adult subjects with post-traumatic stress disorder.

NAME	ADDRESS	CITY	STATE	ZIP	PHONE	STUDY_ID	TITLE	DESCRIPTION
Southern Illinois University, School of Medicine Center for Clinical Research	201 E. Madison St	Springfield	IL	62702	PTSDStudies.com	331-201-00072	Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder	This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of fixed-dose brexpiprazole + sertraline combination treatment in adult subjects with post-traumatic stress disorder.
AMR Conventions Research	1560 Wall St. Suite 329	Naperville	IL	60536	PTSDStudies.com	331-201-00072	Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder	This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of fixed-dose brexpiprazole + sertraline combination treatment in adult subjects with post-traumatic stress disorder.
Neuroscience Research Institute Inc.	27W350 Highlake Rd, Suite 108	Winfield	IL	60190	708-686-0000	331-201-00195	Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (An Open-Label Trial)	This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.
University of Chicago	5841 S. Maryland Ave. MC 3077	Chicago	IL	60637	773-834-3778	331-201-00242	A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder	There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of subjects diagnosed with BPD to provide a pharmacological treatment for BPD.
Neuroscience Research Institute Inc.	27W350 Highlake Road, Suite 108	Winfield	IL	60190	708-686-0000	331-201-00242	A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder	There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of subjects diagnosed with BPD to provide a pharmacological treatment for BPD.
AMR Conventions Research	1560 Wall St. Suite 329	Naperville	IL	60536	630-983-2000	331-201-00242	A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder	There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of subjects diagnosed with BPD to provide a pharmacological treatment for BPD.
Capstone Clinical Research	1880 W Winchester Rd Ste 204	Libertyville	IL	60048	PTSDStudies.com	331-201-00071	Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD	This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of brexpiprazole + sertraline combination treatment in adult subjects with Post-Traumatic Stress Disorder.

Kindly remember to say AWARE for All as your referral source.